News und Analysen
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Humana’s Impact Report Focuses on Building Trust and Transparency in Journey to Health Equity
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, released its 2021 Impact Report, which highlights the company’s continued commitment to its Environment
Acadia Healthcare Announces Date for First Quarter 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2022 results on Tuesday, May 3, 2022, after the close of the market. Acadia will conduct a
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2022 financial results on Wednesday, May 4th, before the market opens. A conference call has been scheduled to
DGAP-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures for the first quarter of 2022 - Increasing difficulties in the supply of electronic components make the lower end of the full-year guidance likely
DGAP-Adhoc: Drägerwerk AG & Co. KGaA: Vorläufige Zahlen für das 1. Quartal 2022 - Zunehmende Schwierigkeiten bei der Lieferung elektronischer Bauteile machen das untere Ende der Jahresprognose wahrscheinlich
Humana Expands National Commitment to Affordable Housing With Additional $25 Million Investment
As part of its national commitment to improve housing stability for vulnerable members and communities, Humana Inc. (NYSE: HUM) today announced an additional $25 million investment in three
Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference Call on May 4th, 2022
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022
Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
As previously disclosed, on January 28, 2022, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic
Humana Throws the First Pitch Event to Connect Minority-Owned Businesses to Top Humana Suppliers
The Supplier Diversity Team of Humana Inc. (NYSE: HUM) hosted the First Pitch, a virtual forum where participants from the Humana Mentor Protégé Program had the opportunity to pitch their business
Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the Commercial Arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has exercised its
DGAP-HV: PAION AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.05.2022 in Aachen mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Sensorion to Attend the Kempen Life Sciences, Cell & Gene Meeting on the Mediterranean Conferences in April 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
Regulatory News:
NANOBOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Pfizer Names David M. Denton Chief Financial Officer
Pfizer Inc. (NYSE: PFE) today announced that David M. Denton will join the Company as Chief Financial Officer (CFO) and Executive Vice President effective May 2, 2022. Mr. Denton will be a member
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today
NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the highlights of over 125 studies enabled by
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present additional positive
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the